ECSP045430A - Terapia de combinación para el tratamiento de cancer - Google Patents

Terapia de combinación para el tratamiento de cancer

Info

Publication number
ECSP045430A
ECSP045430A EC2004005430A ECSP045430A ECSP045430A EC SP045430 A ECSP045430 A EC SP045430A EC 2004005430 A EC2004005430 A EC 2004005430A EC SP045430 A ECSP045430 A EC SP045430A EC SP045430 A ECSP045430 A EC SP045430A
Authority
EC
Ecuador
Prior art keywords
combination therapy
cancer treatment
amount
patient
need
Prior art date
Application number
EC2004005430A
Other languages
English (en)
Inventor
George Sgouros
Victoria M Richon
Paul A Marks
Richard A Rifkind
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of ECSP045430A publication Critical patent/ECSP045430A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

La presente invención se relaciona con un método para el tratamiento de cáncer en un paciente necesitado de ello. El método comprende administrar a un paciente necesitado de ello una primer cantidad de un inhibidor de histona deacetilaza en un primer procedimiento de tratamiento, y una segunda cantidad o dosis de radiación en un segundo procedimiento de tratamiento. El primer y segundo tratamiento juntos comprenden una cantidad terapéuticamente efectiva. La combinación del inhibidor HDAC y la terapia de radiación es terapéuticamente sinergística.
EC2004005430A 2002-04-15 2004-11-15 Terapia de combinación para el tratamiento de cancer ECSP045430A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37303302P 2002-04-15 2002-04-15

Publications (1)

Publication Number Publication Date
ECSP045430A true ECSP045430A (es) 2005-05-30

Family

ID=29250948

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005430A ECSP045430A (es) 2002-04-15 2004-11-15 Terapia de combinación para el tratamiento de cancer

Country Status (12)

Country Link
US (2) US20040018968A1 (es)
EP (1) EP1501489A4 (es)
JP (2) JP2005530734A (es)
CN (1) CN100566711C (es)
AU (1) AU2003226408B2 (es)
BR (1) BR0309280A (es)
CA (1) CA2482508A1 (es)
EC (1) ECSP045430A (es)
HK (1) HK1086488A1 (es)
IL (1) IL164599A0 (es)
MX (1) MXPA04010199A (es)
WO (1) WO2003088954A1 (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601252A1 (ru) * 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
RU2320331C2 (ru) * 2002-03-04 2008-03-27 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. Способ индукции конечной дифференцировки
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
US20050222013A1 (en) * 2003-01-16 2005-10-06 Georgetown University Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy
US8299126B2 (en) * 2003-02-27 2012-10-30 Leonard A. Cohen Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor
US7169801B2 (en) * 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN1839121A (zh) * 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
DK1644049T3 (da) 2003-04-30 2008-02-04 Univ Ramot Fremgangsmåde og anordning til radioterapi
ES2341771T3 (es) 2003-06-27 2010-06-28 Astellas Pharma Inc. Agente terapeutico contra el sarcoma de tejidos blandos.
BRPI0413826A (pt) * 2003-08-26 2006-10-24 Aton Pharma Inc processo de tratamento de cáncer com inibidores de hdac
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
WO2006034207A2 (en) * 2004-09-17 2006-03-30 Vanderbilt University Use of gsk3 inhibitors in combination with radiation therapies
AU2005302291B2 (en) * 2004-11-02 2011-02-10 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
WO2006066133A2 (en) * 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
NZ599464A (en) 2005-02-03 2014-03-28 Topotarget Uk Ltd Combination therapies using hdac inhibitors
NZ548087A (en) * 2005-04-29 2010-10-29 Tomizo Yamamoto Rubber or resin foam containing zirconium or germanium
US7642253B2 (en) * 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
KR101340824B1 (ko) 2005-05-13 2013-12-11 토포타겟 유케이 리미티드 Ｈｄａｃ 억제제의 약학 제형
TWI415603B (zh) 2005-05-20 2013-11-21 Merck Sharp & Dohme １，８－辛二醯基苯胺羥胺酸（ｓｕｂｅｒｏｙｌａｎｉｌｉｄｅ ｈｙｄｒｏｘａｍｉｃ ａｃｉｄ）之調配物及其製配方法
AU2006270322A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2006283677A1 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
RU2436572C2 (ru) * 2005-10-24 2011-12-20 Новартис Аг Комбинация ингибиторов гистондеацетилазы и излучения
CA2622136A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer
CA2627129A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and bortezomib for treating cancer
WO2007054719A2 (en) 2005-11-10 2007-05-18 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent
WO2007061939A2 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100137239A1 (en) 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
KR20090064400A (ko) * 2006-09-28 2009-06-18 머크 앤드 캄파니 인코포레이티드 Ｈｄａｃ 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-ｈｄａｃ 억제제 킬레이트 착물의 약제학적 조성물
JP2010509221A (ja) * 2006-11-03 2010-03-25 ユニバーシテイ・オブ・メリーランド，ボルテイモア 多発性骨髄腫を治療するためにｓａｈａおよびボルテゾミブを使用する方法
MX2009006966A (es) * 2006-12-29 2009-12-09 Gloucester Pharmaceuticals Inc Tratamientos para cancer a base de romidepsina.
CA2674309A1 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation of romidepsin
US8642809B2 (en) * 2007-09-25 2014-02-04 Topotarget Uk Ltd. Methods of synthesis of certain hydroxamic acid compounds
WO2009067543A2 (en) * 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
MX2010009642A (es) * 2008-03-07 2010-09-22 Topotarget As Metodos de tratamiento utilizando infusion continua prolongada de belinostat.
US20100015042A1 (en) * 2008-07-03 2010-01-21 Ramot At Tel Aviv University Ltd. Combine radiation therapy and chemotherapy for treating cancer
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
US20130039882A1 (en) 2009-10-28 2013-02-14 Henry Ford Health System Method to mitigate injury from radiation exposure
US8524762B2 (en) 2010-03-08 2013-09-03 Spectrum Pharmaceuticals, Inc. Thioxanthone-based autophagy inhibitor therapies to treat cancer
SG10201505475XA (en) 2010-07-12 2015-09-29 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
UY34295A (es) * 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida
RU2478374C1 (ru) * 2012-02-06 2013-04-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Минздравсоцразвития России Способ внутриполостной терапии при лечении больных с метастазами рака во влагалище
US8836679B2 (en) * 2012-08-06 2014-09-16 Au Optronics Corporation Display with multiplexer feed-through compensation and methods of driving same
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN103159646B (zh) * 2013-03-19 2014-10-22 广东药学院 一种异羟肟酸类化合物及其制备方法和应用
PL2984184T3 (pl) * 2013-04-09 2021-06-14 The Board Of Trustees Of The University Of Illinois Stosowanie DNQ lub DNQ-87 w połączeniu z inhibitorem PARP1 do leczenia nowotworu
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
RU2017127597A (ru) 2015-01-23 2019-02-25 Темпл Юнивёрсити-Оф Дзе Коммонвелс Систем Оф Хайе Эдьюкейшен Применение короткоцепочечных жирных кислот для профилактики рака
CN104788391B (zh) * 2015-04-21 2017-03-08 中国医学科学院医药生物技术研究所 肉桂酰中性红酰胺(ca‑pz)及其制备与应用
CA3014674C (en) * 2016-02-15 2024-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods comprising fixed intermittent dosing of cediranib
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
EP3621692A4 (en) 2017-05-11 2021-01-13 Alpha TAU Medical Ltd. POLYMER COATINGS FOR BRACHYTHERAPY DEVICES
KR20200139722A (ko) 2018-04-02 2020-12-14 알파 타우 메디컬 리미티드 방사성 핵종의 제어된 방출
CA3114299A1 (en) * 2018-11-01 2020-05-07 Alpha Tau Medical Ltd. Intratumoral alpha-emitter radiation and activation of cytoplasmatic sensors for intracellular pathogen
US11654300B2 (en) 2020-01-28 2023-05-23 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy
JP2023541635A (ja) * 2020-09-15 2023-10-03 オンコインベント アクスィエ セルスカプ Ｄｎａ修復阻害剤との組み合わせによる放射性核種療法での使用のためのラジウム２２４とプロジェニーとの調製
WO2022130195A1 (en) 2020-12-16 2022-06-23 Alpha Tau Medical Ltd. Diffusing alpha-emitters radiation therapy with enhanced beta treatment

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5330744A (en) * 1988-11-14 1994-07-19 Sloan-Kettering Institute For Cancer Research Method for increasing sensitivity to chemically induced terminal differentiation
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
EE200100187A (et) * 1998-09-25 2002-08-15 Warner-Lambert Company Vähi kemoteraapia atsetüüldinaliiniga kombinatsioonis gemtsitabiini, kapetsitabiini või tsisplatiiniga
TR200101049T2 (tr) * 1998-10-13 2002-01-21 Fujisawa Pharmaceutical Co. Ltd. Siklik tetrapeptid bileşiği ve kullanımı
EA200601252A1 (ru) * 1999-09-08 2006-10-27 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
ATE392210T1 (de) * 1999-10-07 2008-05-15 Aguilar Cordova Carlos Estuard Methoden zur behandlung von festen tumoren und metastasen mit gentherapie
WO2001038322A1 (en) * 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
US6544957B2 (en) * 2000-01-04 2003-04-08 The Johns Hopkins University Methods and reagents for facilitating transcription
EP2093292A2 (en) * 2000-03-24 2009-08-26 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
ES2277923T3 (es) * 2000-07-06 2007-08-01 Sumitomo Chemical Company, Limited Insecticidas.
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
AU2001287157A1 (en) * 2000-09-12 2002-03-26 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
GB0023983D0 (en) * 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
US20020103192A1 (en) * 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
WO2002055017A2 (en) * 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) * 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6693132B2 (en) * 2000-12-21 2004-02-17 Beacon Laboratories, Inc. Methods for using alkanoyloxymethyl esters
US20020183388A1 (en) * 2001-02-01 2002-12-05 Gudas Lorraine J. Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
EP1408946A4 (en) * 2001-03-27 2004-06-09 Circagen Pharmaceutical HISTONE DEACETYLASE INHIBITORS
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US20040142859A1 (en) * 2002-05-02 2004-07-22 Steffan Joan S. Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors
WO2002102323A2 (en) * 2001-06-14 2002-12-27 Bristol-Myers Squibb Company Novel human histone deacetylases
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
RU2320331C2 (ru) * 2002-03-04 2008-03-27 МЕРК ЭйчДиЭйСи Рисерч, ЛЛС. Способ индукции конечной дифференцировки
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
WO2003083067A2 (en) * 2002-03-28 2003-10-09 Brigham And Women's Hospital, Inc. Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
WO2003088954A1 (en) * 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
AU2003291097A1 (en) * 2002-11-20 2004-06-15 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
CN1839121A (zh) * 2003-04-01 2006-09-27 斯隆-凯特林癌症研究所 异羟肟酸化合物及其使用方法
BRPI0413826A (pt) * 2003-08-26 2006-10-24 Aton Pharma Inc processo de tratamento de cáncer com inibidores de hdac
CN1964714B (zh) * 2003-08-29 2011-09-28 Hdac默克研究有限责任公司 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途

Also Published As

Publication number Publication date
US20090054720A1 (en) 2009-02-26
JP2005530734A (ja) 2005-10-13
MXPA04010199A (es) 2005-07-05
AU2003226408B2 (en) 2007-06-14
CN100566711C (zh) 2009-12-09
AU2003226408A1 (en) 2003-11-03
WO2003088954A1 (en) 2003-10-30
HK1086488A1 (en) 2006-09-22
CN1728991A (zh) 2006-02-01
EP1501489A1 (en) 2005-02-02
JP2009114207A (ja) 2009-05-28
CA2482508A1 (en) 2003-10-30
US20040018968A1 (en) 2004-01-29
BR0309280A (pt) 2005-02-22
IL164599A0 (en) 2005-12-18
EP1501489A4 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
ECSP045430A (es) Terapia de combinación para el tratamiento de cancer
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
CY1106259T1 (el) Συνδυασμενη θepαπεια που πepιλαμβανει zd6474 κι ενα ταξανιο
CO6361942A2 (es) Terapia de combinacion con epoxicetonas peptidicas
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
CR8163A (es) Composicion farmaceutica que contiene un inhibidor de histona desacetilasa
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
AR050418A1 (es) Dosificacion fija de anticuerpos her
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
UY29274A1 (es) Composicion farmaceutica para tratar la hipertension, que comprende telmisartano e hidroclorotiazida
CO5590913A2 (es) Terapia de combinacion antivirica
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
AR119033A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
NO20056170L (no) Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839
NO20064753L (no) Kombinasjonsterapi
UY26422A1 (es) Método para administrar un inhibidor de fosfodiesterasa 4
ATE353650T1 (de) Kombinationstherapie zur behandlung von krebs
NO20064754L (no) Kombinasjonsterapi
WO2023164455A3 (en) Compositions and methods to modulate the immune system
MX2023015097A (es) Tratamiento de sintomas asociados a neoplasias mieloproliferativas.